Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding
- Conditions
- Hepatic Impairment; Renal Impairment
- Interventions
- Drug: Plasma Sampling
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02998775
- Locations
- 🇺🇸
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Inc., Orlando, Florida, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 971
- Registration Number
- NCT02952820
- Locations
- 🇵🇱
Facility # 2, Warszawa, Poland
🇯🇵Eisai Trial Site 3, Yokohama, Kanagawa, Japan
🇯🇵Eisai Trial Site 2, Yokohama, Kanagawa, Japan
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
- Conditions
- Non Clear Cell Renal Cell Carcinoma (nccRCC)
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02915783
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02914314
- Locations
- 🇺🇸
Axcess Medical Research, Loxahatchee Groves, Florida, United States
🇺🇸Pediatric Epilepsy And Neurology Specialists, Tampa, Florida, United States
🇺🇸NW FL Clinical Research Group, LL-ClinEdge- PPDS, Gulf Breeze, Florida, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT02873156
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02859207
Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures
- Conditions
- Partial-Onset or Primary Generalized Tonic-Clonic Seizures
- Interventions
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT02849626
- Locations
- 🇯🇵
Eisai Trial Site #1, Yokohama-shi, Japan
🇰🇷Facility #3, Seoul, Korea, Republic of
🇪🇸Facility #2, Barcelona, Spain
Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT02834793
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇮🇳Synexus Affiliate - Mallikatta Neuro Center, Mangalore, Karnataka, India
🇦🇺Royal Brisbane & Women's Hospital, Brisbane, Australia
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1069
- Registration Number
- NCT02811861
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Ramat-Gan, Israel
🇯🇵Facility #2, Tokyo, Japan
🇺🇸Mount Sinai Medical Center, Miami Beach, Florida, United States
Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02809768